OCUL vs. TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, PCVX, KRYS, and RYTM
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.
Ocular Therapeutix vs. Its Competitors
TG Therapeutics (NASDAQ:TGTX) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.
TG Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics presently has a consensus target price of $40.80, indicating a potential upside of 13.40%. Ocular Therapeutix has a consensus target price of $17.33, indicating a potential upside of 80.37%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than TG Therapeutics.
In the previous week, TG Therapeutics had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 5 mentions for TG Therapeutics and 1 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.21 beat TG Therapeutics' score of 0.97 indicating that Ocular Therapeutix is being referred to more favorably in the news media.
TG Therapeutics has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
TG Therapeutics has a net margin of 10.13% compared to Ocular Therapeutix's net margin of -323.09%. TG Therapeutics' return on equity of 18.88% beat Ocular Therapeutix's return on equity.
Summary
TG Therapeutics beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
This page (NASDAQ:OCUL) was last updated on 7/8/2025 by MarketBeat.com Staff
